Novel Liquid Oral CBD Formulations, Published Apr 23
Summary
The USPTO published patent application US20260108540A1 on April 23, 2026, covering stable liquid oral pharmaceutical formulations of synthetic Cannabidiol (CBD). The application, filed June 24, 2023 (Application No. 19120456), names inventors Chandrashekhar KOCHERLAKOTA and Srinivas ARUTLA. The formulations comprise synthetic CBD combined with pharmaceutical excipients including solvents, oils, organoleptic modifiers, buffers, and surfactants.
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published a patent application for novel liquid oral formulations of Cannabadiol (CBD) derived from synthetic sources. The application covers stable pharmaceutical compositions combining synthetic CBD with various excipients such as solvents, oils, buffers, and surfactants. CPC classifications indicate applications in cannabinoid derivatives and oral pharmaceutical formulations.
Pharmaceutical companies developing CBD-based therapeutics may want to review this filing for potential freedom-to-operate implications. The use of synthetic CBD rather than plant-derived CBD may offer advantages in consistency and regulatory compliance for pharmaceutical applications. Inventors Chandrashekhar KOCHERLAKOTA and Srinivas ARUTLA are named as applicants.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NOVEL LIQUID ORAL FORMULATIONS OF CANNABIDIOL
Application US20260108540A1 Kind: A1 Apr 23, 2026
Inventors
Chandrashekhar KOCHERLAKOTA, Srinivas ARUTLA
Abstract
The present invention relates to stable liquid oral pharmaceutical formulations of cannabidiol (CBD) and also discloses methods of producing stabilized formulations of cannabidiol using cannabidiol from a synthetic source. The stable formulations of the present invention comprise of synthetic CBD and one or more pharmaceutically acceptable excipients selected from solvents, oils, organoleptic modifiers, buffers, surfactants etc.
CPC Classifications
A61K 31/658 A61K 9/0053 A61K 9/08 A61K 47/10 A61K 47/14 A61K 47/22 A61K 47/26 A61K 47/44
Filing Date
2023-06-24
Application No.
19120456
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.